How has been the historical performance of Bandaram Pharma?

Answer:The historical performance of Bandaram Pharma shows a steady growth in net sales and profit over the past three years.

Breakdown:
Bandaram Pharma's net sales increased from 18.73 Cr in Mar'23 to 34.08 Cr in Mar'24, and further to 36.96 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, reaching 36.96 Cr in Mar'25. The company's total expenditure also rose, from 17.57 Cr in Mar'23 to 34.14 Cr in Mar'25, primarily driven by higher raw material costs and employee expenses. Operating profit, excluding other income, remained stable at 2.82 Cr in both Mar'24 and Mar'25, while the overall operating profit increased slightly to 2.91 Cr in Mar'25. Profit before tax improved from 0.33 Cr in Mar'23 to 1.32 Cr in Mar'25, and profit after tax followed suit, rising to 0.99 Cr in Mar'25 from 0.26 Cr in Mar'23. The earnings per share also showed a positive trend, increasing to 0.82 in Mar'25. On the balance sheet, total assets grew from 20.17 Cr in Mar'23 to 38.92 Cr in Mar'25, with total liabilities also increasing to 38.92 Cr in Mar'25. Cash flow from operating activities remained negative at -4.00 Cr in Mar'25, consistent with the previous year, while cash flow from financing activities was positive at 5.00 Cr in Mar'25. Overall, Bandaram Pharma's financial performance reflects a trajectory of growth in sales and profitability, despite challenges in cash flow management.